GLP-1 agonists, including exenatide, liraglutide, lixisenatide, albiglutide, and taspoglutide can stimulate insulin secretion (similar to other insulin secretagogues), improve peripheral insulin resistance, decrease body weight, and reduce the risk of hypoglycemia for Type 2 diabetic patients [63]. This evidence concerns the gene GCG and type 2 diabetes mellitus.